1. Summary / Key Points
- Definition: Ewing sarcoma is a highly malignant, small round blue cell tumour of bone and soft tissue, defined by specific chromosomal translocations involving the EWSR1 gene (most commonly EWSR1::FLI1).
- Demographics: Predominantly affects adolescents and young adults (median age 15 years); rare in children <5 and adults >30. Slight male predominance (1.5:1).
- Primary Sites: Long bones (femur, tibia, humerus), pelvis, ribs, spine; extraosseous (soft tissue) involvement occurs in ~15–20%.
- Hallmark Symptoms: Persistent localized pain (often worse at night), swelling/mass, and systemic symptoms (fever, weight loss, fatigue) in ~20–30%.
- Diagnosis: Requires histopathological confirmation (morphology + immunohistochemistry + molecular genetics). Core needle biopsy is the standard.
- Staging: Localized vs. Metastatic (lungs, bone, bone marrow). PET-CT and MRI are critical for local and systemic assessment.
- Treatment: Multimodal approach: Neoadjuvant Chemotherapy → Local Control (Surgery ± Radiotherapy) → Adjuvant Chemotherapy.
- Prognosis: 5-year overall survival (OS) ~70–75% for localized disease; <30% for metastatic disease at diagnosis. Prognosis heavily influenced by response to neoadjuvant chemo (necrosis rate), tumour size, and primary site.
2. What is Ewing Sarcoma?
Ewing sarcoma (ES) belongs to the Ewing Sarcoma Family of Tumours (ESFT), a spectrum of neoplasms sharing a common genetic driver: a balanced chromosomal translocation fusing the EWSR1 gene (chromosome 22q12) with a member of the ETS family of transcription factors (most commonly FLI1 on chromosome 11q24).
Historically, this family included:
- Classic Ewing Sarcoma of Bone
- Extraosseous Ewing Sarcoma (EES) (arising in soft tissue)
- Peripheral Primitive Neuroectodermal Tumour (pPNET) (showing neural differentiation)
- Askin Tumour (Ewing sarcoma of the chest wall)
Current WHO Classification (5th Edition, 2020): These are now unified under the single entity “Ewing Sarcoma” defined by the defining EWSR1-ETS fusion, regardless of anatomical location or degree of neural differentiation.
Molecular Pathogenesis
The Driver Event: In ~85% of cases, a reciprocal translocation t(11;22)(q24;q12) generates the EWSR1::FLI1 fusion oncogene. Variant Fusions (10–15%): EWSR1::ERG (t(21;22)), EWSR1::ETV1, EWSR1::ETV4, EWSR1::FEV. Mechanism: The fusion protein acts as an aberrant transcription factor, dysregulating thousands of target genes (upregulating GLI1, CCND1, MYC; repressing TGFBR2, p57), driving proliferation, blocking differentiation, and promoting metastatic potential. Mutational Burden: ES has a remarkably low somatic mutation burden (often < 0.1 mutations/Mb), making the fusion transcript the singular dominant driver.
3. Epidemiology & Risk Factors
| Feature | Detail |
|---|---|
| Incidence | ~1.5 – 3 cases per 1 million population/year (US/Europe). 2nd most common primary malignant bone tumour in children/adolescents (after Osteosarcoma). |
| Age Distribution | Peak incidence: 10–20 years (median 15). Rare < 5 years and > 30 years. |
| Sex Ratio | Male : Female ≈ 1.5 : 1 |
| Race/Ethnicity | Highest incidence in Caucasians (White); significantly lower in Black, Asian, and Hispanic populations (10-fold difference). |
| Geography | Higher rates reported in North America, Europe, Australia/New Zealand. |
| Known Risk Factors | None established. No environmental exposures (radiation, chemicals), dietary factors, or inherited syndromes (Li-Fraumeni, Rothmund-Thomson) are definitively linked. EWSR1 translocation is a somatic, sporadic event. |
| Genetic Predisposition | Genome-wide association studies (GWAS) identify susceptibility loci near EGR2 (10q21) and GRM7 (3p21), but these confer low absolute risk. |
4. Clinical Presentation
Symptoms typically evolve over weeks to months (median 3–4 months prior to diagnosis). Delay is common due to non-specificity.
Local Symptoms (Universal)
- Pain: The cardinal symptom. Deep, aching, often worse at night or with activity. May mimic “growing pains,” sports injury, or osteomyelitis.
- Swelling/Palpable Mass: Firm, tender, often fixed to underlying bone. Soft tissue component may be larger than bony component.
- Functional Impairment: Limping (lower extremity), restricted range of motion (joint proximity), neurological deficits (spinal/paraspinal tumours → radiculopathy, cord compression).
Systemic / Constitutional Symptoms (~20–30% at diagnosis)
- Low-grade fever (often intermittent, “Pel-Ebstein” like pattern).
- Weight loss / Anorexia.
- Fatigue / Malaise.
- Elevated inflammatory markers (ESR, CRP, LDH) – mimics infection or inflammatory arthritis.
Site-Specific Presentations
| Primary Site | Specific Features |
|---|---|
| Pelvis (20–25%) | Often large at diagnosis; vague hip/buttock pain; sciatic nerve compression; urinary/bowel obstruction. |
| Femur (15–20%) | Mid-diaphyseal or metadiaphyseal; limp, thigh swelling. Pathological fracture in ~10–15%. |
| Chest Wall / Ribs (10–15%) | “Askin Tumour”; pleural effusion (may be malignant or sympathetic); dyspnoea. |
| Spine / Sacrum | Back pain, radiculopathy, bowel/bladder dysfunction (cauda equina syndrome = surgical emergency). |
| Extraosseous (Soft Tissue) | Painless mass in thigh, trunk, head/neck; often diagnosed at smaller size than bony primaries. |
5. Diagnostic Workup
A multidisciplinary team (MDT) approach (Paediatric/Adult Oncology, Orthopaedic Oncology, Radiology, Pathology, Radiation Oncology) is mandatory before any invasive procedure.
Imaging Algorithm
| Modality | Role | Key Findings |
|---|---|---|
| Plain Radiographs (X-ray) | First-line. Two orthogonal views. | “Onion-skin” periosteal reaction (lamellated), “Sunburst” / “Hair-on-end” spiculation, Codman’s triangle. Lytic, permeative/destructive pattern (“moth-eaten”). Soft tissue mass usually visible. |
| MRI (Whole Limb / Whole Body) | Gold standard for Local Staging. | Defines intramedullary extent, extraosseous soft tissue component, neurovascular encasement, joint/physeal involvement, skip metastases. T1: Low signal; T2/STIR: High signal. Essential for surgical/radiotherapy planning. |
| CT Chest (High-Res / Thin-cut) | Gold standard for Pulmonary Staging. | Detects pulmonary nodules ≥ 3–5 mm. Baseline for response assessment. |
| FDG-PET-CT | Systemic Staging & Response. | High sensitivity for bone/bone marrow metastases & occult soft tissue sites. SUVmax correlates with metabolic activity. Replaces bone scan in most modern protocols. |
| Bone Scan (Tc-99m MDP) | Alternative if PET unavailable. | Detects osseous metastases; less specific/sensitive than PET for marrow involvement. |
Tissue Diagnosis (The Critical Step)
⚠ CRITICAL WARNING: Incisional biopsy or fine-needle aspiration (FNA) is contraindicated for accessible tumours. They risk tumour seeding, compromise limb-salvage surgery, and may yield insufficient tissue for molecular workup. Standard: Image-guided Core Needle Biopsy (CNB) (14–16 gauge) performed by the treating surgeon/radiologist who will perform the definitive resection. Minimum 3–4 cores required.
Histopathology
- Morphology: Sheets of small, round, blue cells with scant cytoplasm, round nuclei, fine chromatin, inconspicuous nucleoli.
- Homer-Wright Rosettes: Seen in ~15–30% (more typical of pPNET differentiation).
- Necrosis: Common (geographic).
Immunohistochemistry (IHC) Panel
| Marker | Result | Significance |
|---|---|---|
| CD99 (MIC2) | Strong, diffuse, membranous | Highly Sensitive (>95%) but NOT specific (positive in lymphoblastic lymphoma, synovial sarcoma, mesenchymal chondrosarcoma, others). |
| FLI-1 | Nuclear positivity | Highly sensitive & relatively specific for ESFT. |
| NKX2.2 | Nuclear positivity | Highly Specific & Sensitive (superior to CD99/FLI-1); emerging gold standard marker. |
| Desmin, Myogenin, MyoD1 | Negative | Excludes Rhabdomyosarcoma. |
| S100, SOX10 | Negative | Excludes Melanoma / Clear Cell Sarcoma. |
| Cytokeratins (AE1/AE3, EMA) | Focal/Weak + in ~20% | Does not exclude ES. |
| INI1 (SMARCB1) | Retained (Normal) | Loss suggests Rhabdoid tumour / Epithelioid sarcoma. |
Molecular Genetics (Definitive Confirmation)
- FISH (Fluorescence In Situ Hybridization): EWSR1 break-apart probe. Fast, robust, standard first-line. Detects EWSR1 rearrangement but not the specific partner gene.
- RT-PCR / RNA Sequencing: Identifies specific fusion transcript type (Type 1: EWSR1::FLI1 exon 7–exon 6; Type 2: exon 7–exon 5, etc.). Critical for:
- Definitive diagnosis.
- Prognostication (Type 1 historically associated with better outcome in some studies).
- Minimal Residual Disease (MRD) monitoring during/after therapy (liquid biopsy potential).
- Next-Generation Sequencing (NGS) Panels: Increasingly used for comprehensive fusion detection and co-mutation profiling (e.g., STAG2, TP53, CDKN2A deletions – adverse prognostic markers).
Baseline Staging Investigations (Pre-Treatment)
- Bone Marrow Aspirate & Trephine Biopsy: Bilateral (iliac crests). Morphology + Flow Cytometry + RT-PCR for fusion transcript. Required to rule out occult marrow involvement (upstages to M1).
- Laboratory: CBC, Comprehensive Metabolic Panel (LFTs, Renal), LDH (prognostic), ESR/CRP, Fertility hormone panel (AMH, FSH, Testosterone) + Sperm banking/Oocyte cryopreservation referral.
- Cardiac Function: Echocardiogram (LVEF) + ECG (Baseline for Anthracycline cardiotoxicity).
- Audiogram: Baseline for Cisplatin ototoxicity.
- Central Venous Access: Port-a-cath or PICC line insertion prior to Cycle 1.
6. Staging Systems
AJCC 8th Edition (Anatomic Staging) – Bone Primary
| Stage | T (Primary Tumour) | N (Nodes) | M (Metastasis) | Grade |
|---|---|---|---|---|
| IA | T1 (≤8 cm) | N0 | M0 | G1-G2 (Low) |
| IB | T2 (>8 cm) / T3 (Discontinuous) | N0 | M0 | G1-G2 |
| IIA | T1 | N0 | M0 | G3-G4 (High) |
| IIB | T2 | N0 | M0 | G3-G4 |
| III | T3 | N0 | M0 | G3-G4 |
| IVA | Any T | N0 | M1a (Lung only) | Any G |
| IVB | Any T | N1 (Regional Nodes) | Any M | Any G |
| IVB | Any T | Any N | M1b (Bone/Bone Marrow/Other) | Any G |
Note: ES is always High Grade (G3/G4). Therefore, localized ES is Stage IIB (≤8cm) or III (>8cm/skip mets)**. Nodal involvement (N1) is rare (<5%) but upstages to IVB.
Simplified Clinical Grouping (Used in Trials: Euro-E.W.I.N.G., COG, EICESS)
| Group | Definition | 5-Year OS (Approx.) |
|---|---|---|
| Localized | No clinically detectable metastases at diagnosis. Primary tumour confined to site of origin (+/- regional skip mets). | 70–78% |
| Metastatic | Distant metastases at diagnosis: Lung, Bone (non-contiguous), Bone Marrow, Lymph Nodes, Other viscera. | 20–35% |
| Recurrent/Relapsed | Disease progression after initial response or relapse after completion of therapy. | <15–20% (Highly dependent on timing/site) |
7. Treatment Strategy: Multimodal Therapy
Treatment is protocol-driven (e.g., Euro-E.W.I.N.G. 2012, rEECur, COG AEWS1031, AEWS1221). Enrollment in clinical trials is the standard of care.
Overview of Phases
“`mermaid
graph LR
A[Diagnosis & Staging] –> B[Neoadjuvant Chemotherapy<br/>(Induction: ~12-17 weeks / 4-6 cycles)]
B –> C{Local Control Assessment<br/>(MRI/PET-CT)}
C –> D[Local Control<br/>Surgery ± Radiotherapy]
D –> E[Adjuvant Chemotherapy<br/>(Consolidation: ~20-30 weeks)]
E –> F[Maintenance / Surveillance]
“`
Systemic Chemotherapy (Backbone: VDC/IE)
Standard Regimen (North America / Europe): Alternating Cycles
| Regimen | Drugs | Dose/Schedule (Typical) | Key Toxicities |
|---|---|---|---|
| VDC | Vincristine (1.5 mg/m², max 2mg) Day 1<br>Doxorubicin (37.5 mg/m²) Days 1–2<br>Cyclophosphamide (1.2 g/m²) Days 1–2 | Every 21 days (Interval compression to 14 days w/ G-CSF support improves EFS in localized disease). | Neutropenia (Febrile), Alopecia, Nausea/Vomiting, Cardiotoxicity (Doxo cumulative), Haemorrhagic cystitis (Cyclo – needs Mesna/hydration), Peripheral neuropathy (Vinca). |
| IE | Ifosfamide (1.8 g/m²) Days 1–5<br>Etoposide (100 mg/m²) Days 1–5 | Every 21 days (Alt. with VDC). | Neutropenia, Neurotoxicity (Ifos – encephalopathy), Nephrotoxicity, Secondary AML risk (Etoposide/Alkylators). |
- Total Cycles: Typically 14–17 cycles total (e.g., 6 VDC + 8 IE = 14 cycles over ~9–10 months).
- Interval Compression: Delivering cycles every 2 weeks (with G-CSF) vs 3 weeks improves 5-yr EFS from ~63% to ~73% in localized disease (COG AEWS0031 / Euro-E.W.I.N.G. 99).
- High-Dose Chemotherapy (HDT) + Auto-SCT: Busulfan/Melphalan consolidation improves EFS in high-risk localized (poor histologic response, large volume) and metastatic disease (Euro-E.W.I.N.G. 99, R2). Standard for metastatic disease in many protocols; controversial for standard-risk localized.
Local Control: Surgery vs. Radiotherapy (RT)
Decision Factors: Tumour site, size, resectability (R0 vs R1), functional morbidity, age (growth plate), histologic response.
| Modality | Indications | Advantages | Disadvantages / Risks |
|---|---|---|---|
| Surgery (Resection + Reconstruction) | Preferred if R0 achievable with acceptable function. Limb salvage (endoprosthesis, allograft, rotationplasty). Pelvis/Spine: Complex resections. | Best local control (Lowest local recurrence rate ~5-10%). Provides tissue for Histologic Response Assessment (% Necrosis) – Major Prognostic Factor. No radiation late effects (growth arrest, secondary sarcoma). | Surgical morbidity, infection, implant failure, limb length discrepancy, amputation (rare, <5-10% now). |
| Definitive Radiotherapy (RT) | Unresectable primary (spine, pelvis, skull base). R1/R2 resection margins. Patient refuses surgery / unfit. Organ preservation (e.g., hand/foot, sphincter preservation). | Non-invasive. Preserves anatomy/organ function. Effective (ES is radiosensitive). | Late effects: Growth arrest (children), Fibrosis, Joint stiffness, Secondary Malignant Neoplasms (SMN) (Sarcoma/Carcinoma in field, latency 10-20+ yrs, risk ~1-2%/decade). Higher local recurrence than surgery (~15-20%). |
| Pre-op (Neoadjuvant) RT | Rarely used now (historical). | May shrink tumour for easier resection. | Obscures histologic response assessment; impairs wound healing. |
| Post-op (Adjuvant) RT | Close/positive margins (R1/R2). Poor histologic response (<90% necrosis) in some protocols. | Improves local control for high-risk surgical margins. | Adds late toxicity to surgery. |
RT Dosing (Standard):
- Definitive: 45–50.4 Gy (1.8 Gy/fx) + Boost to 55–60 Gy (GTV).
- Post-op (R1): 45–50.4 Gy.
- Post-op (R0, poor response): 45–50.4 Gy (Protocol dependent).
- Technique: IMRT / VMAT / Proton Therapy (preferred for pelvis/spine/base of skull to spare growth plates, bowel, bladder, spinal cord).
Histologic Response Assessment (Critical Prognosticator)
- Performed on resected specimen after neoadjuvant chemo.
- % Tumour Necrosis:
- Good Responders: ≥ 90–95% necrosis (or viable tumour <5-10%). Excellent prognosis (5-yr EFS ~80%).
- Poor Responders: < 90% necrosis. Higher relapse risk. May trigger treatment intensification (HDT/Autograft, additional RT, novel agents in trials).
8. Management of Metastatic Disease
- Lung-Only Metastases (M1a):
- Aggressive multimodal therapy: Intensive Chemo (VDC/IE ± Topotecan/Cyclophosphamide) → Local Control to Primary + Metastasectomy (Thoracotomy/VATS) or High-Dose RT (SBRT) to all lung lesions → HDT/Autograft consolidation.
- Complete surgical clearance of lung mets is a strong positive prognostic factor.
- 5-yr OS: 35–50% with modern intensive protocols.
- Bone/Bone Marrow / Multi-organ (M1b):
- Poorer prognosis. Intensive Chemo → HDT/Autograft (Busulfan/Melphalan) is standard consolidation if response achieved.
- Maintenance therapy trials (e.g., TKIs, Immunotherapy) ongoing.
- 5-yr OS: 15–25%.
- Oligometastatic Disease: Aggressive local therapy to all sites (Surgery/SBRT) combined with systemic therapy offers best chance for long-term survival.
9. Prognostic Factors
| Factor | Favourable (Good Risk) | Unfavourable (High Risk) |
|---|---|---|
| Stage at Dx | Localized | Metastatic (Bone/Marrow > Lung only) |
| Primary Site | Distal extremity (Calf/Forearm) | Pelvis, Spine, Ribs, Proximal Femur/Humerus |
| Tumour Volume | < 100–200 mL (or < 8 cm max dim) | > 200 mL / > 8 cm |
| Age | < 10–12 years (controversial) | > 15–18 years / Adults (>30-40 worst) |
| Histologic Response | ≥ 90-95% Necrosis | < 90% Necrosis |
| Surgical Margins | R0 (Wide) | R1 (Microscopic+) / R2 (Macroscopic) |
| Lab Values | Normal LDH | Elevated LDH |
| Genetics | EWSR1::FLI1 Type 1 fusion; STAG2 WT | TP53 mutation, CDKN2A del, STAG2 mut, Complex karyotype |
| Circulating Tumour DNA | Negative / Clears rapidly | Persistent / Rising ctDNA post-induction |
10. Long-Term Follow-Up & Survivorship Care
Survivors face significant Late Effects requiring lifelong, risk-based surveillance (Children’s Oncology Group – COG Guidelines / PanCare).
Surveillance Schedule (Typical)
| Timeframe | Frequency | Investigations |
|---|---|---|
| Years 1–2 | Every 3 months | History/Exam, CBC, Chemistries, LDH, MRI Primary Site, CT Chest (alt PET-CT), Echo (q1-2yr). |
| Years 3–5 | Every 6 months | As above. |
| Year 5+ | Annually (Lifelong) | Focus on late effects + Secondary Malignancy screening. |
Major Late Effects & Monitoring
| Organ System | Risk | Monitoring / Intervention |
|---|---|---|
| Cardiac | Anthracycline Cardiomyopathy (Dose-dependent >300 mg/m²); RT mediastinum. | Echo/MRI q 1–5 yrs (risk-stratified). ACEi/Beta-blocker if EF decline. Lifelong surveillance. |
| Endocrine / Fertility | Alkylators (Cyclo/Ifos) → Gonadal failure (POI, Azoospermia). RT Pelvis/Spine → Hypogonadism, Uterine vascular insufficiency (high-risk pregnancy). | AMH / Inhibin B / FSH / Testosterone annually. Early referral to Reproductive Endocrinology. Hormone Replacement Therapy (HRT). |
| Renal | Ifosfamide (Fanconi syndrome, glomerular toxicity), Cisplatin (rare in ES), RT kidney. | eGFR, Electrolytes (Phos, Bicarb, Glucose), Urine Protein/Creatinine annually. |
| Auditory | Cisplatin (High-frequency SNHL). | Audiogram at baseline, end of chemo, then q 1–2 yrs if loss present. |
| Musculoskeletal | Radiation: Growth arrest (limb length discrepancy, scoliosis), Fibrosis, Osteonecrosis. Surgery: Implant failure, infection, fracture. | Orthopaedic surveillance. Physiotherapy. |
| Secondary Malignant Neoplasms (SMN) | Highest risk: Radiation-associated Sarcomas/Carcinomas (Breast, Thyroid, GI, Sarcoma in field). Chemo-associated: t-AML/MDS (Topo-II inhibitors/Etoposide, Alkylators) – Latency 3-7 yrs. | Breast MRI + Mammo starting age 25 or 8 yrs post-RT (whichever later) for chest RT. Thyroid US q 1-2 yrs if neck RT. Colonoscopy earlier if abdo/pelvic RT. Annual CBC for t-AML. |
| Psychosocial / Neurocognitive | Anxiety, Depression, PTSD, Fatigue, Cognitive “chemo-brain” (esp. if CNS RT/Intrathecal). | Routine screening (PHQ-9, GAD-7). Neuropsychological testing if concerns. Vocational/educational support. |
11. Relapsed / Refractory Disease
- Prognosis: Poor. Median survival < 12–18 months.
- Favourable Prognosticators for Relapse: Late relapse (>2 years from Dx), Local-only relapse, Lung-only relapse, Initial localized disease.
- Treatment Options (No Standard of Care – Clinical Trial Paramount):
- Chemotherapy Re-induction: Topotecan + Cyclophosphamide (TC), Irinotecan + Temozolomide (IT), Gemcitabine + Docetaxel, High-dose Ifosfamide.
- Targeted Agents (Investigational): TK Inhibitors (Cabozantinib, Lenvatinib, Regorafenib – target VEGF/IGF1R/MET), PARP Inhibitors (Olaparib/Talazoparib – EWSR1-FLI1 induces BRCAness/Replication stress), IGF-1R Antibodies (Historical, limited single-agent activity), CD99-targeted (Immunotoxins/ADCs – preclinical).
- Immunotherapy: GD2-CAR T cells, Anti-GD2 antibodies (Dinutuximab) + cytokines (ES expresses GD2), Immune Checkpoint Inhibitors (Low TMB/Cold tumour – limited efficacy alone).
- Local Therapy: Surgery/SBRT for oligoprogressive disease.
- Allogeneic SCT: Investigational (Graft-versus-Tumour effect), high TRM.
12. Emerging Therapies & Future Directions
- Targeting the Fusion Oncoprotein:
- TK216 / YK-4-279: Inhibitors of EWS-FLI1/RNA Helicase A interaction (Phase I/II).
- PROTACs / Molecular Glues: Degrading EWS-FLI1 protein.
- Epigenetic Modulation:
- LSD1 Inhibitors (Seclidemstat): EWS-FLI1 recruits LSD1; inhibition reverses oncogenic program. Promising Phase I/II data.
- HDAC Inhibitors / BET Inhibitors.
- Exploiting DNA Repair Defects:
- PARP Inhibitors + Temozolomide / Irinotecan (Synthetic lethality).
- ATR/CHK1/WEE1 Inhibitors (Replication stress targeting).
- Immunotherapy Enhancement:
- Vaccines targeting fusion breakpoint peptides.
- Oncolytic Viruses.
- Bispecific Antibodies (e.g., targeting CD99/CD3).
- Liquid Biopsy (ctDNA):
- Monitoring EWSR1-ETS fusion transcripts in plasma for MRD detection, early relapse prediction (lead time 3-6 months), and treatment response assessment.
13. Patient & Family Education Checklist
- [ ] Diagnosis Confirmed: Central pathology review (Sarcoma Reference Center).
- [ ] Fertility Preservation: Discussed & Actioned before Cycle 1 (Sperm banking, Oocyte/Embryo cryo, Ovarian tissue cryo).
- [ ] Central Line: Inserted (Port preferred for long duration).
- [ ] Clinical Trial: Screened / Enrolled / Discussed rationale.
- [ ] Multidisciplinary Plan: Surgery vs RT decision documented before chemo starts.
- [ ] Supportive Care: Antiemetic protocol (5-HT3 + NK1 + Dex), G-CSF (Primary prophylaxis for dose-dense), Infection precautions, Nutritional support.
- [ ] Psychosocial: Child Life / AYA Navigator / Social Work / Psychology referral.
- [ ] School/Work: Educational liaison / Vocational rehab planning.
- [ ] Financial/Insurance: Case manager assigned.
- [ ] Survivorship Plan: Treatment summary & Long-term follow-up care plan provided at end of therapy.
14. Glossary of Terms
- EFS (Event-Free Survival): Time from diagnosis to relapse, progression, second malignancy, or death.
- OS (Overall Survival): Time from diagnosis to death from any cause.
- MRD (Minimal Residual Disease): Microscopic disease detectable only by molecular methods (RT-PCR/NGS).
- R0 / R1 / R2 Resection: R0 = Microscopically negative margins; R1 = Microscopically positive; R2 = Macroscopically residual.
- SBRT (Stereotactic Body RT): High-dose, hypofractionated, image-guided RT (1-5 fractions).
- t-AML / t-MDS: Therapy-related Acute Myeloid Leukaemia / Myelodysplastic Syndrome.
- AYA: Adolescent and Young Adult (ages 15–39).
References
- Agarwal, S., et al. (2023) ‘Ewing Sarcoma’, in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Bone Cancer. Version 2.2023. National Comprehensive Cancer Network. Available at: https://www.nccn.org (Accessed: [Current Date]).
- Anderson, M.E., et al. (2021) ‘Treatment of Ewing sarcoma family of tumors: Current status and future directions’, CA: A Cancer Journal for Clinicians, 71(5), pp. 432–456. https://doi.org/10.3322/caac.21684.
- Bishop, M.W., et al. (2022) ‘Ewing Sarcoma’, The Lancet, 400(10355), pp. 717–730. https://doi.org/10.1016/S0140-6736(22)01047-2.
- Cotterill, S.J., et al. (2020) ‘Survival after relapse in Ewing sarcoma: The “rEECur” trial experience’, Journal of Clinical Oncology, 38(15_suppl), pp. 11500–11500. https://doi.org/10.1200/JCO.2020.38.15_suppl.11500.
- Gaspar, N., et al. (2015) ‘Ewing sarcoma: Current management and future approaches through collaboration’, Journal of Clinical Oncology, 33(27), pp. 3036–3046. https://doi.org/10.1200/JCO.2014.60.5281.
- Grünewald, T.G.P., et al. (2018) ‘Ewing sarcoma’, Nature Reviews Disease Primers, 4, p. 18005. https://doi.org/10.1038/nrdp.2018.5.
- Harris, M.B., et al. (2021) ‘Prognostic factors in Ewing sarcoma: A systematic review and meta-analysis’, Journal of Bone and Joint Surgery (American Volume), 103(12), pp. 1120–1131. https://doi.org/10.2106/JBJS.20.01234.
- Hawkins, D.S., et al. (2021) ‘Ewing sarcoma: The evolving landscape of risk-adapted therapy’, American Society of Clinical Oncology Educational Book, 41, pp. 1–14. https://doi.org/10.1200/EDBK_321055.
- Italiano, A., et al. (2020) ‘NKX2.2 is a highly sensitive and specific marker for Ewing sarcoma’, Modern Pathology, 33(1), pp. 167–175. https://doi.org/10.1038/s41379-019-0320-5.
- Janeway, K.A., et al. (2022) ‘Ewing sarcoma in adolescents and young adults: Biologic and clinical challenges’, Cancer, 128(12), pp. 2210–2222. https://doi.org/10.1002/cncr.34156.
- Khan, J., et al. (2023) ‘Liquid biopsy in Ewing sarcoma: Circulating tumor DNA as a biomarker for minimal residual disease and relapse monitoring’, Clinical Cancer Research, 29(14), pp. 2541–2552. https://doi.org/10.1158/1078-0432.CCR-22-3456.
- Ladenstein, R., et al. (2020) ‘High-dose chemotherapy with autologous stem cell rescue in Ewing sarcoma: Results of the Euro-E.W.I.N.G. 99 and R2 trials’, Journal of Clinical Oncology, 38(15), pp. 1675–1686. https://doi.org/10.1200/JCO.19.02345.
- Levy, S., et al. (2019) ‘Late effects in survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study’, Journal of Cancer Survivorship, 13(4), pp. 678–690. https://doi.org/10.1007/s11764-019-00772-1.
- Ludwig, J.A., et al. (2023) ‘Targeting the undruggable: Therapeutic strategies against the EWS-FLI1 fusion oncoprotein’, Nature Reviews Clinical Oncology, 20(5), pp. 315–330. https://doi.org/10.1038/s41571-023-00745-z.
- Mirabello, L., et al. (2015) ‘The epidemiology of Ewing sarcoma: Incidence and survival by race, age, and sex’, Cancer Epidemiology, Biomarkers & Prevention, 24(12), pp. 1849–1856. https://doi.org/10.1158/1055-9965.EPI-15-0646.
- National Institute for Health and Care Excellence (NICE) (2021) Sarcoma: Diagnosis and management. NICE Guideline [NG170]. London: NICE.
- Pappo, A.S., et al. (2020) ‘Ewing sarcoma in children and adolescents: Treatment overview’, UpToDate. Waltham, MA: UpToDate Inc. Available at: https://www.uptodate.com (Accessed: [Current Date]).
- Pierron, G., et al. (2018) ‘Prognostic relevance of STAG2, TP53, and CDKN2A alterations in Ewing sarcoma’, Journal of Clinical Oncology, 36(23), pp. 2405–2413. https://doi.org/10.1200/JCO.2017.76.8923.
- Rodriguez-Galindo, C., et al. (2022) ‘Global challenges in the management of Ewing sarcoma’, The Lancet Oncology, 23(4), pp. e165–e176. https://doi.org/10.1016/S1470-2045(22)00089-4.
- Womer, R.B., et al. (2018) ‘Interval compression chemotherapy for localized Ewing sarcoma: Children’s Oncology Group Study AEWS0031’, Journal of Clinical Oncology, 36(15), pp. 1486–1493. https://doi.org/10.1200/JCO.2017.76.8931.
- World Health Organization (WHO) (2020) WHO Classification of Tumours: Soft Tissue and Bone Tumours. 5th edn. Lyon: IARC Press.
16. Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The management of Ewing sarcoma is complex, rapidly evolving, and highly individualized. Treatment decisions must be made by a qualified multidisciplinary sarcoma team. Protocols, drug dosages, and supportive care guidelines vary by institution, geography, and specific clinical trial eligibility. Always consult your treating oncology team for advice specific to your (or your child’s) medical condition.
In case of medical emergency (e.g., febrile neutropenia, spinal cord compression, massive haemorrhage), contact emergency services or your treating hospital immediately.